STOPINFECTIONS is a research project funded by the competitive program RETOS-COLABORACION 2019 of the State Research Agency of the Spanish Ministry of Science and Innovation. The goal of the project is to execute activities to support taking Vaxdyn’s technology for vaccine development to file a permit to enter clinical phase for prevention of pneumonia resistant to antibiotics.
Execution of STOPINFECTIONS in 2020-2022 is made by a consortium led by Vaxdyn. The partners are the National Microbiology Center (CNM) of the Spanish Institutes of Health “Carlos III” in Madrid, the Barcelona-based international pharmaceutical manufacturer Laboratorios Reig Jofré, and Leitat Technological Center (Barcelona).
ACINETOCLINIC (2016-2019) was a project funded by the competitive program RETOS-COLABORACION 2016 of the Spanish Ministry of Science and Innovation, co-financed with the ERDF Programme of the European Union.
The project finished with completion of preclinical research of AcinetoVax, the first universal vaccine against drug resistant Acinetobacter baumannii (VXD-001). The research performed allowed conversion of a single product into a technological platform to deliver multivalent vaccine candidates against Gram-negative bacteria. These results made possible to execute the business plan of Vaxdyn and attract private investors that today are making possible to deliver vaccines for tackling antibiotic-resistant infections.
Execution was made by a consortium led by Vaxdyn. The partners were the Andalusian Healthcare Service, the University of Seville, Barcelona-based international pharmaceutical manufacturer Laboratorios Reig Jofré, and Leitat Technological Center (Barcelona).
1-HEALTH-RESPIRA (2018-2019) was a project funded by the competitive program RETOS-COLABORACION 2017 of the Spanish Ministry of Science and Innovation, co-financed with the ERDF Programme of the European Union.
The project finished with experimental trials in porcine of vaccines to prevent respiratory viral and bacterial diseases in piglets that are currently treated with antibiotics, leading to the appearance and spread of antibiotic-resistant pathogens. Vaxdyn tested its technological platform for raising immunity in pigs for applications in the veterinary industry, leading a consortium formed by the following partners: the biotech group ADL Bionatur Solutions, who tested viral subunit vaccines; the Institute of Parasitology and Biomedicine “López Neyra” of the CSIC in Granada, who carried mice immunological assays; the biotech company Bionanoplus (Pamplona, Spain), who formulated the vaccine active principles to test intranasal versus intramuscular delivery; and the Faculty of Veterinary Sciences of the University of Córdoba, who managed the experimental work on pigs.